Not as magnesium-rich Ingredients: Rated 5.5/10 Uses cane sugar and natural flavors
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes
ACC American College of Cardiology, AHA American Heart Association, ESC European Society of Cardiology, ADA American Diabetes Association, GLP-1 RA glucagon-like peptide 1 receptor agonists, T2DM type 2 diabetes mellitus, ASCVD atherosclerotic cardiovascular disease, CV cardiovascular, CVD cardiovascular disease, MACE major adverse cardiovascular event, SGLT2i sodium-glucose co-transporter 2 inhibitors, BMI body mass index, MI myocardial infarction, HFpEF heart failure with preserved ejection fraction a ACC/AHA and ESC utilize class of recommendation (1, 2a, 2b, 3) which highlights the overall benefit of a treatment compared to its risks
Research shows that approximately 12 percent of patients pause or discontinue GLP-1 treatment due to digestive discomfort